AstraZeneca Investor Day Presentation Deck

Prostate is the second most common cancer in male patients mCRPC therapies are limited; mostly monotherapy, including in first line NHA naïve at mCRPC ~50% NHA experienced in mCRPC ~50% Urologist-led Primary/ adjuvant Hormone sensitive Prostatectomy /RTX +/- Adjuvant ADT Biochemical recurrence ADT Urologists and oncologists mHSPC Recurrent ADT +/- docetaxel ADT + NHA De-novo ADT +/- docetaxel +/- RTX ADT + NHA nm CRPC doce- taxel/ other NHA Castration resistant Urologists and oncologists 1st-line metastatic HRRm 20-30%² HRRm 20-30% NHA or docetaxel NHA or docetaxel Lynparza (PROfound) NHA or docetaxel ~80% diagnosed here ~20% diagnosed here 22 Source: AstraZeneca estimates. Indicative populations. Not to scale 1. Rawla P. World J Oncol. 2019; 10(2):63-89. 2. Mateo, J, et al. New England Journal of Medicine, 2015, 373(18), pp.1697 - 1708. ADT = androgen deprivation therapy; RTX = radiation therapy; nmCRPC = non-metastatic castration resistant prostate cancer 2nd-line+ metastatic HRRm 20-30% Lynparza (PROfound) chemo/palliative care HRRm 20-30% chemo/palliative care chemo/palliative care 3

View entire presentation